上海君實生物醫藥科技股份有限公司
Shanghai Junshi Biosciences Co., Ltd.*
( 於中華人民共和國註冊成立的股份有限公司 )
股份代號 : 1877
2022 年 度 報 告
* 僅供識別
2
4
12
14
59
72
89
148
175
179
181
183
185
188
295
2
1
2
3 3
Roy Steven Herbst
Roy Steven Herbst
3
985,689,871 219,295,700 H
766,394,171 A
36 58 2 10 1003
H
16 200 H
348 5
H www.junshipharma.com
16 17
H 01877
A 688180
1 2022 6 29
2 2022 12 8
3
4
2022 12 31 1,453 2021 64%
736
2021 79%
2
2,384 2021 15%
(i) (ii)
(iii)
4,643 A 2022 12 2
3,748
840
2,492
2,386 2021 1,667
5
(ADCs)
4
30
PARP III 20
2022 2
III
JUPITER-15 NCT05180734
2022 2 JS112 Aurora A IND NMPA
2022 3
NMPA
2022 3
3 I Acta Pharmacologica Sinica
2022 3 JS107 Claudin18.2 MMAE IND NMPA
2022 3 JS001sc IND NMPA
2022 4 TAB009/JS009 CD112R IND
FDA
2022 4
Nature
Signal Transduction and Targeted Therapy STTT IF 38.104
6
2022 4
FDA
5 FDA
FDA
2022 5 JS105 PI3K-α IND NMPA
2022 5
PAXLOVID COVID-19
III (NCT05341609)
COVID-19
The New England Journal of Medicine
NEJM 176.082
2022 5
sNDA NMPA
2022 6 JS116 KRASG12C IND NMPA
2022 6 JS113 EGFR IND NMPA
2022 7 JS105 PI3K-α (HR)
2(HER-2) PIK3CA IND
FDA
2022 7 JS203 CD20 CD3 IND NMPA
2022 8 JS110 XPO1 IND FDA
2022 8 TAB009/JS009 CD112R IND NMPA
2022 9
EGFR ALK
sNDA NMPA
NMPA
7
2022 10 JS015 DKK1 IND NMPA
2022 11
NMPA
2022 12
EMA
2022 1 Coherus 2021 2 Coherus
TIGIT (TAB006/JS006)
Coherus TAB006/JS006 TAB006/JS006
Coherus 3,500 Coherus
2.55 TAB006/JS006 Coherus
18%
2022 3
JS120 IDH1 JS121 SHP2 JS122 FGFR2
JS123 ATR
2022 6
2022 12 Hikma Hikma
20 Hikma
1,200 20%
Hikma Hikma
8
2022 5 NMPA
CGMP 12,000
42,000
2022 12 53.95 17 7,000 A
3,776.50
2023 1 (SARS-CoV-2)1
NMPA COVID-19
2023 1 JS401 ANGPTL3 mRNA siRNA IND
NMPA
2023 1
III Neotorch NCT04158440 IDMC
EFS
2023 2
IV
III TORCHLIGHT NCT04085276
IDMC
2023 2 PCSK9 JS002
III JS002-
003 JS002-006
9
2023 2
MHRA
2023 3 JS010 CGRP IND NMPA
2023 3 Excellmab
Excellmab 40%
Excellmab Excellmab
452
10
12 31
2018 2019 2020 2021 2022
934 775,089 1,594,897 4,024,841 1,453,493
667 684,405 1,222,366 2,766,654 927,211
(716,500) (744,233) (1,665,639) (728,181) (2,582,095)
(714,593) (741,055) (1,687,567) (718,579) (2,650,714)
(714,654) (740,744) (1,687,567) (708,955) (2,454,686)
61 (311) – (9,624) (196,028)
(1.19) (0.95) (2.02) (0.80) (2.60)
(1.19) (0.95) (2.02) (0.80) (2.60)
12 31
2018 2019 2020 2021 2022
1,347,126 2,511,324 3,312,147 5,218,981 5,371,381
2,910,184 1,911,116 4,698,717 5,831,739 7,204,905
4,257,310 4,422,440 8,010,864 11,050,720 12,576,286
465,112 828,548 677,022 701,903 1,007,782
471,065 605,376 1,492,582 2,016,635 1,774,254
936,177 1,433,924 2,169,604 2,718,538 2,782,036
3,321,133 2,988,516 5,841,260 8,332,182 9,794,250
11
12 31
2018 2019 2020 2021 2022
*
2,928 775,089 1,594,897 4,024,841 1,453,493
(1,269) 677,105 1,214,645 2,773,235 938,772
(722,854) (747,729) (1,668,607) (730,534) (2,584,077)
(721,582) (744,550) (1,690,536) (720,932) (2,652,695)
(1.21) (0.96) (2.03) (0.81) (2.60)
(2.03) (0.81) (2.60)
12 31
2018 2019 2020 2021 2022
1,340,137 2,500,838 3,298,693 5,190,020 5,342,012
2,910,184 1,911,116 4,698,717 5,844,891 7,216,484
4,250,321 4,411,954 7,997,410 11,034,911 12,558,496
465,111 855,700 697,140 717,084 1,015,725
471,067 578,225 1,472,464 2,001,453 1,766,311
936,178 1,433,925 2,169,604 2,718,537 2,782,036
3,314,143 2,978,029 5,827,806 8,316,374 9,776,460
*
12
2022
2023 1
COVID-19
50
PD-1
PCSK9 senaparib PARP VEGF
first-in-class tifcemalimab BTLA 2022 ASCO ADC
78.77%
Hikma
20
Coherus Coherus
2022 2 TIGIT (TAB006/JS006)
Coherus
13
2022 5 NMPA
CGMP 12,000 42,000
FDA Coherus
2022 12
17 7,000 A 37.765
ADC
2023 3 30
14
first-in-class
best-in-class
JS001
NMPA PD-1
6
12
EGFR
ALK
tifcemalimab (first-inhuman) BTLA FDA NMPA
IND Ib/II
2020
COVID-19 (JS016)
(ADCs)
15
2022 5
sNDA NMPA 2022 9
EGFR ALK
sNDA NMPA
NMPA
3
PD-1
4,000 2,000
137
93 104 93
33
1,000
736
79%
2
sNDA
2023
16
2023 1 28 (SARS-CoV-2)1
NMPA
COVID-19
RdRp RdRp
2022 3
NMPA 2022 5 2022 11
NMPA
(JS002) PCSK9
2023 2 JS002-003 JS002-006
JS002-003
JS002-006
II III 2023
PARP senaparib(JS109)
III 2022 8 senaparib
FDA III
2023
(JS501) III
17
tifcemalimab ASCO
2022 6 (ASCO)
PD-1 BTLA tifcemalimab ASCO
40
tifcemalimab
ASCO 2022 tifcemalimab #230 #297
tifcemalimab BTLA
2022 12 64 (American Society of Hematology) ( #1613)
tifcemalimab I 28 tifcemalimab
85% PD-1 39.3% ORR
85.7% DCR
15 30
2023 1
III Neotorch NCT04158440 IDMC
EFS
2023 2
IV
III TORCHLIGHT NCT04085276
IDMC
IV PD-L1
PFS PD-L1 OS
2023 NMPA
sNDA
18
2022 1 Coherus 2021 2 Coherus
TIGIT (TAB006/JS006) Coherus
TAB006/JS006 TAB006/JS006 Coherus
3,500 Coherus 2.55
TAB006/JS006 Coherus 18%
2022 3 JS120
IDH1 JS121 SHP2 JS122 FGFR2 JS123
ATR
2022 6
FDA
BLA
BLA FDA
Coherus FDA
EMA MHRA
MAA
19
2022 12 Hikma Hikma
20
1,200 20% Hikma
Hikma
2023 3 Excellmab
Excellmab 40%
Excellmab Excellmab
452
Excellmab
2022 5 NMPA
CGMP 12,000
42,000
20
ESG
2022 12
53.95 17 7,000 A
3,776.50
5,997
ESG ESG
ESG ESG 2022 8
A A 2022 9 5
ESG 10% ESG ESG
2,961 995 989 561
IT
21
NCT03013101 2018 12 17 NMPA
FDA
NCT02915432 2021 2 NMPA FDA
NCT03113266 2021 4 NMPA
FDA
NCT03581786 2021 11 NMPA FDA EMA MHRA
NCT03829969 2022 5 NMPA EMA MHRA FDA
NCT03856411 EGFR 2022 9 NMPA
NCT04772287
NCT04085276
NCT03924050 EGFR TKI
NCT04012606 FDA
JS001
NCT04848753
NCT03430297
NCT04523493
NCT04723004
NCT03859128
NCT05342194
NCT04394975
NCT05302284
NCT05180734
FDA
/
NMPA
NCT03474640 FDA
2023 3 30
JS011 JS013 CD93 JS006 TIGIT JS007 CTLA-4 Tifcemalimab BTLA Senaparib PARP PD-1
JS018 IL-2 JS104 Pan-CDK JS009 CD112R JS014 IL-21 JS005 IL-17A VEGF TNF-α
JS114 Nectin4 ADC JS115 BCMA ADC JS015 DKK1 JS105 PI3K-α PCSK9 RdRp
JS120 IDH1 JS121 SHP2 JS107 Claudin18.2 ADC JS111 EGFR exon 20 *S
JS122 FGFR2 JS123 ATR JS112 Aurora A JS113 EGFR 4th Gen
JS205 EGFR×cMet JS206 IL-2×PD-1 JS001sc PD-1 JS110 XPO1
JS207 PD-1×VEGF JS208 JS203 CD3×CD20 JS019 CD39
JS209 CD112R×TIGIT JS211 PD-L1× JS003 PD-L1 JS012 Claudin 18.2
JS401 ANGPTL3 VV993 3CL JS101 Pan-CDK JS108 Trop2 ADC
JS116 KRAS JS201 PD-1×TGF-β
* FDA
JS008 JT109
JS010 CGRP JS103 Uricase
UBP1213sc BLyS JS026 S
22
23
Coherus
Hikma
PD-1 FDA EMA MHRA
(JS001) 20
Tifcemalimab
BTLA
(TAB004/JS004)
JS006 Coherus
TIGIT
(TAB006)
JS009 CD112R/
(TAB009) PVRIG
JS105 PI3K-α
JS110 XPO1
Eli Lilly and Company
S COVID-19 15 EUA
(JS016)
24
TAB001/JS001
PD-1
2
6
2018 12
2021 2 12
2021 4 2021 11
2022 5
EGFR ALK
2022 9
CSCO
CSCO CSCO CSCO CSCO
CSCO
3 PD-1
137
93 104 93
33
25
1,000
736
79%
2
sNDA
2023
15 30
26
2022 2
III
JUPITER-15 NCT05180734
2022 5
sNDA NMPA
17
6 42%(HR=5.8,P<0.0001) PD-L1
2022 9
EGFR ALK
sNDA NMPA
NMPA
EGFR/ALK
PFS OS PD-L1
245
PFS 9.7
4.2 HR=0.48[95%CI 0.35-0.66] p 0.0001
OS
52% HR=0.48[95%CI 0.32-0.71]
2023 1
III Neotorch NCT04158440 IDMC
EFS NMPA
2023 2
IV
III TORCHLIGHT NCT04085276
IDMC NMPA
27
EGFR(-)
vs vs
EGFR(+)
vs vs
vs vs vs
vs vs vs
vs vs vs
vs vs vs
/
28
2022 4 FDA
FDA
FDA
2022 7 FDA
BLA
2022 12
(MAA) EMA
2023 2
(MAA) MHRA
2022 3 JUPITER-06 Cell Press Cancer Cell IF: 38.585
TP
PFS OS PD-L1
2022 3 2022 ASCO (ASCO Plenary Series) CHOICE-01
EGFR/ALK PFS 51% OS
31%
29
2022 4 113 (AACR)
(RM NPC)III JUPITER-02
CT226
PFS 21.4 8.2 13.2
48%
2022 5 Cell Press The Innovation
(BTCs)II
2022 6 ASCO 30
2022 7 Annals of Oncology IF 51.769
-α2b HDI High-Dose Interferon-α2b (MuM)
II (RFS) HDI
PD-L1 HDI
MuM
2022 9 (ESMO)2022
III NeoTAP01 2 EFS
2022 10 Journal of Experimental & Clinical Cancer Research IF:12.658
(HNSCC)
2022 12 (ESMO-IO)
4 I/II
30
2022 12 ASCO Journal of Clinical Oncology IF 50.739
PD-1 PD-L1 JUPITER-06
PD-1
PD-L1 PD-L1
2023 3 GEMOX
II Nature Signal Transduction
and Targeted Therapy, STTT , IF 38.104
JT001/VV116
RdRp
RdRp
2022 12 29 The New England Journal of Medicine NEJM
176.082 VV116
) (PAXLOVID)
COVID-19 III (NCT05341609)
NEJM
PAXLOVID
31
2023 1 28
NMPA COVID-19
III (NCT05582629)
COVID-19
28 SARS-CoV-2
1,277
11 COVID-19 =0 2 2
COVID-19
32
Tifcemalimab TAB004/JS004
Tifcemalimab (first-in-human) B T
(BTLA) BTLA tifcemalimab Ib/II
tifcemalimab
ASCO 2022 tifcemalimab
tifcemalimab BTLA
I
(NCT04477772) tifcemalimab (R/R)
31 R/R 15 16
4 1~10 61.3% 19 PD-1/L1
25 1 (PR) 7 (SD) 6
PD-1 3 PR(ORR 50%) 1 SD 2022 4 26
31.9 (DLT) tifcemalimab R/R
HVEM PD-L1
Tifcemalimab R/R
2022 64 (ASH) tifcemalimab I
28 tifcemalimab 85%
PD-1 39.3% ORR 85.7% DCR
(DoR)
FDA NMPA tifcemalimab 2023
III
33
UBP1211
2022 3
NMPA 2022 5
2022 11
NMPA
34
JS002
PCSK9
2023 2 JS002-003 JS002-006
JS002-003
JS002-006
II III
PCSK9 PCSK9 2023
PARP senaparib JS109
Senaparib ADP (PARP) 2020 8
senaparib
PARP senaparib
50% 2020 8 20 2020 8 26 Senaparib
III 2022 8
senaparib FDA
III 2023
IL-17A JS005
JS005 IL-17A JS005 IL-17
JS005
JS005 I II
II
III
35
TIGIT TAB006/JS006
TAB006/JS006 TIGIT TAB006/JS006
TIGIT-PVR TIGIT T cell immunoglobulin and
ITIM domain,T ITIM NK T
PVR NK T
PD-1 T TIGIT PD-1/PD-L1
2021 1 TAB006/JS006 NMPA IND
2021 2 TAB006/JS006 FDA IND TAB006/JS006 I
TAB006/JS006 II
CTLA-4 JS007
JS007 CTLA-4 T
-4 Cytotoxic T lymphocyte-associated antigen-4 CTLA-4 T
JS007 CTLA-4 CTLA-4 B7 CD80 CD86 T
ipilimumab
JS007 ipilimumab
2021 6 JS007 NMPA JS007 I
36
CD112R TAB009/JS009
TAB009/JS009 CD112R CD112R
PVRIG
CD112R PVR
T NK CD112R TIGIT CD112
CD112R T NK TAB009/JS009
CD112R CD112R CD112 T NK
TIGIT PVR PVR CD112
CD112 CD112R TAB009/JS009 TIGIT (TAB006/JS006)
T CD112R
TIGIT PD-1 T
CD112R 2022 4 2022 8 TAB009/JS009 IND FDA NMPA
TAB009/JS009 I
21 (HSA) JS014
JS014 21 (HSA) HSA
IL-21 IL-21R
JS014 2019 6 Anwita Biosciences,
Inc.
IL-21 JS014 2021 8 JS014 IND NMPA
JS014 I
37
DKK1 JS015
J S015 D K K1
DKK1(Dickkopf-1) DKK
Wnt JS015 DKK1
DKK1 LRP5/6 Wnt JS015 DKK1
JS015
JS015
2022 10 JS015 IND NMPA JS015 I
PI3K-α JS105
JS105 PI3K-α
HR HER-2 PIK3CA
JS105
JS105 PI3K-α Piqray Alpelisib
HR HER-2 PIK3CA PI3K-α 2022 5 2022
7 JS105 IND NMPA FDA JS105 I
Claudin18.2 -MMAE JS107
JS107 Claudin18.2 -MMAE (Monomethyl auristatin E)
Claudin18.2 (ADCs) JS107
Claudin18.2 MMAE
JS107 (ADCC) (CDC)
MMAE JS107
JS107
2022 3 JS107 IND NMPA JS107 I
38
XPO1 JS110
JS110 XPO1 JS110
XPO1 p53 JS110
JS110
JS110 2021 4 2022 8 JS110 IND
NMPA FDA JS110 I
EGFR exon20 JS111
JS111 EGFR EGFR EGFR
10% EGFR exon20 T790M G719X 18-21
EGFR-TKI EGFR exon20 EGFR
JS111
T790M EGFR EGFR EGFR exon20
EGFR JS111 EGFR exon20 EGFR
2021 4 JS111 NMPA JS111 I/II
(NCT04993391) JS111
Aurora A JS112
JS112 Aurora A Aurora A Aurora
Aurora A KRAS G12C KRAS G12C
RB1 RB1
Aurora A 2022 2 JS112 IND NMPA
JS112 I
EGFR JS113
JS113 first-in-class EGFR EGFR JS113
EGFR
EGFR Del19/T790M/C797S L858R/T790M/C797S TKI
EGFR 2022 6 JS113 IND NMPA
JS113 I
39
CD20 CD3 JS203
JS203 CD20 CD3 B
CD20 B B CD3 T
CD3 T T JS203 CD20
CD3 T CD3 CD20 T
JS203 JS203
CD20 CD3 Lunsumio mosunetuzumab FDA
2022 7 JS203 IND NMPA
JS203 I
JS001sc JS001sc
JS001sc JS001sc PD-1
PD-1 PD-1 PD-L1 PD-L2 T
JS001sc
0.3mg/kg JS001sc
JS001sc
PD-
(L)1
JS001sc I
3 RNA RNA JS401
JS401 3 RNA RNA
ANGPTL3 (LPL)
(EL) ANGPTL3
JS401 N (GalNac) ANGPTL3 mRNA
ANGPTL3
ANGPTL3 Evkeeza (Evinacumab-dgnb) siRNA
2023 1 JS401 IND NMPA
40
121 94 27
2022 12 53.95 17 7,000 A
377,650
41
1.
2022 12 31 1,453 2021 64% (i)
753 2021 76%
2 (ii) 476 2021 86%
(a) Eli Lilly and Company 2021
2021 (b) Coherus
2021 TAB006/JS006
2.
2,384 2021 315 15%
1,705 462
115 49 53
2021 16% 13%
43% 2021 9% 10%
(i) (ii)
(iii)
42
3.
716 2021 19 3%
399 288
4 25 2021
18% 2021
17% 73% 32% (i)
(ii) (iii)
4.
578 2021 70 11%
264 115 97
29 73
2021 18% 71%
2021 5% 6% 4% 2022 (i)
(ii)
5.
2022 12 31 2021 12 31 3,505 5,997
(i) A (ii) (iii)
43
6.
12 31
2022 2021
(2,650,714) (718,579)
91,911 192,754
(50,052) 39,937
(2,608,855) (485,888)
7. H A
H H 3,003 2022
12 31 H 2018 12 11
2019 8 29 2019 2020 8 28 H
2019 2020
2021 2022 2022
12 31 12 31 12 31
2019 2020
12 31 6 30
1,952,203 65% 2,162,440 72% 2,372,677 79% 10,883 10,883 2,372,677 – 2022 12
31
JS001 1,201,356 40% 1,201,356 40% 1,291,457 43% 4,447 4,447 1,291,457 – 2022 6 30
480,542 16% 480,542 16% 600,678 20% 6,436 6,436 600,678 – 2022 12 31
1a
JS004
270,305 9% 480,542 16% 480,542 16% – – 480,542 – 2021 12 31
1b
750,847 25% 540,610 18% 330,373 11% 571 571 330,373 – 2022 12 31
1c
2 2 2
300,339 10% 300,339 10% 300,339 10% 301 301 334,872 – 2022 12 31
3,003,389 100% 3,003,389 100% 3,003,389 100% 11,755 11,755 3,037,922 –
44
45
1. 2019 2019 8
a.
b.
c.
2. 35
[2020]940 2020 7 A
8,713 55.50 4,836
339 4,497 A
2020 7 8 A
2021 2022 2022
12 31 12 31 12 31
1,200,000 110,182 110,182 1,200,000 – 2022 12 31
700,000 – – 700,000 – 2020 12 31
800,000 15,970 25,897 809,927 – 2020 6 30
1,796,978 1,244,292 525,501 1,078,187 751,217 2024 12
31
4,496,978( 1)
1,370,444( 2)
661,580( 2)
3,788,114( 1)
751,217( 1 2)
1. (i) (ii)
2. (i) 2022 12 31 (ii) 2021 12 31
46
2021 6 23 J.P. Morgan Securities plc
2021 6 16
36,549,200 H
H 70.18 H 2021 6 16 H
70.65 2,104
(a)
(b)
2021 6 16 2021 6 23
2022 12 31 2,092
47
2022 12 31
2021 2022 2022
12 31 12 31 12 31
815 219 210 806 8 2025 6 30
1 1 1 1 – 2022 12 31
285 224 224 285 – 2022 6 30
1,003 230 246 1,000 – 2022 12 31
2,104 1
674 2
681 2
2,092 1
8 1 2)
1. (i) (ii)
2. (i) 2022 12 31 (ii) 2021 12 31
48
[2022]2616 2022 12 6
A 7,000
53.95 3,777 32
3,745 2022 3 7
2022 6 14 2022 12 6 A A 57.72
A
2022
12 31
3,464 140 3,324 2026 12 31
281 70 211 2026 12 31
3,745 210 3,535
2022 2021 12 31
49
(a)
12 31
2022 2021
(2,386,067) (718,557)
12 31
2022 2021
917,465,166 892,659,689
2022 12 31 2022 7 5
1,845,200 2022 11 1 269,740 2022 12 2 A
70,000,000
(b)
2022 12 31 2021 12 31
2022 12 31 2021 12 31
2022 2 28 80,000,000
50%
50
2022 12 31
15,000,000
12 31
2022 2021
a 156,235 155,218
b 12,182 46,664
c 604,323 551,651
d – 20,000
772,740 773,533
e 137,457 253,575
910,197 1,027,108
(a)
(b)
(c)
92,163,000 2021 78,569,000
(d) 20,000,000 4,687,301 2022
12 31
(e) Coherus
51
2021 12 31 485 2022 12 31 599
12 31
2022 2021
338,942 353,059
219,213 102,665
40,866 28,877
599,021 484,601
2021 12 31 1,293 2022 12 31 233
12 31
2022 2021
232,743 1,285,243
– 7,690
232,743 1,292,933
(18) –
232,725 1,292,933
2022 12 31 2021 12 31
52
12 31
2022 2021
17,933 13,780
15,238 16,796
a 239,822 397,383
b 293,562 351,534
c
5,853 4,976
d
– 7,719
11,579 11,579
2,719 –
e
79,424 125,873
42,370 154,005
708,500 1,083,645
(614) (590)
707,886 1,083,055
345,137 549,141
362,749 533,914
707,886 1,083,055
(a)
(b)
(c)
53
(d) 2021 11 19,298,000
40% 7,719,000 60% 11,579,000
(e) 2022 12 31 79,424,000 2021
125,873,000
42,370,000 2021 154,005,000 2022 12 31
2021 12 31 1,908 2022 12 31 1,338
12 31
2022 2021
281,600 196,205
133,382 89,874
a 415,751 227,709
65,783 64,569
75,205 54,149
b 69,097 932,509
c 16,639 15,742
191,903 213,777
35,187 20,579
2,898 757
50,955 91,653
1,338,400 1,907,523
2021 12 31
8,400,000
1,224,000 Anwita
2022 12 31
54
0 90 2021 15 60
(a)
(b) 30
(c)
2022 12 31
434 1.9% 3.9%
480 2022 5 13 2030 5 12
2022 12 31 241 LPR
450 2022 5 20 2030 5 20
2022 12 31 70 LPR
i ii iii
55
2022 12 31
12 31
2022 2021
672,430 664,538
146,166 55,611
818,596 720,149
391,750 10,596
84,836 30,000
397,708 220,000
357,038 240,000
1,231,332 500,596
2022 2021 12 31
2022 12 31
935 2021 12 31 664 41%
7,700
56
100% 2022 12 31
2022 12 31
2022 12 31
1.
57
2.
3.
4.
58
5.
6.
4+7
7.
59
49
2015 3
2013 4
2013 1 2013 3 2015 11
430598.NEEQ 2016 6
2013 9 2015 11 2007 2
1996 7 2007 12
2017 2022 12 31
218,324,586 A 2,600 H
60
61
2018 6
2018 1
1994 5 1997 1 (NIH) AIDS
WESTAT 1997 2 2009 12 FDA
2009 9 2018 1
2007 1 2010 12 (Johns Hopkins)
2010 11 2012 11 2012 1 2014 12
1984 7 1987 10
1994 8
2022 12 31 956,000 A
58
2016 12
2016 12
20 1986 7 1997 12
1997 12 2004 1
2004 1 2019 3
600867.SH 2019 6
1986 7
2022 12 31 3,657,600 A
61
46
2015 3
2014 1
10
2003 2007 2007 2010
HumanZyme Inc. 2010 10 2013 11 MedImmune Inc.
TopAlliance
JS001 JS002 JS003
1997 7 2003 9
2022 12 31 13,652,000 A
62
55
2016 12
2012 12
20 2011 11 2015 11
2013 10 2022 12
2022 12 2016
4 2021 9 2021 12
2012 12 2012 12 2013 3
1997 1 2004 5
2005 5 2008 10 Viron Therapeutics Inc. 2008 11 2011 9
2011 2
1988 7 1995 7
2005
2022 12 31 9,120,000 A
63
47
2016 12
2014 6
2003 1 2004 4 2004 5
2010 12 2011 1 2011 10
2011 10 2014 6 Amplimmune Inc.
TopAlliance JS002
JS003
1998 6 2003 1
(Nature Communications)
(Science Advances) (Immunity) Jem Blood JI
2022 12 31 1,200,000 A
64
51
2022 6
2022 4
20 1995 8 2005 9 301
2005 10 2012 10
2012 10 2015 9
2015 9 2022 4
1989 1995 2005 8
49
2016 12
2013 6
20 2003 3 2007 9
2007 8 2009 2 Trellis Biosciences 2009 2 2013 5 Amgen
2015 3 2020 10 2016 12
2020 10 14 JS002 JS003
1994 7 2002 5
(Nature) (Science) (EMBO)
65
54
2015 5
2015 5
20 1991 1993
1993 1996 1996 6
2010 12
2010 10 2013 10
002650.SZ 2011 6 2018 11
832549.NEEQ 2017 8 2013 4
2013 7
2017 7
1989 7 1990 1
2022 12 31 204,418,286 A 2,600 H
66
65
2018 6
2018 6
35 1999 B7-H1 PD-L1
PD-L1 1999 2002 PD-1/PD-L1
2006 PD-1 PD-L1
1990 1997 (Bristol-Myers Squibb
Company) 1997 1999 2004 2011
2011
2017 4 17
138.25
14.63%
2016 9 27 307.5
1982 1986 1989
William B. Coley 2014 AAI-Steinman 2016 Warren Alpert 2017
2018
67
Roy Steven Herbst 60
2018 6
2018 6
Herbst 1991 1997 1998 2011
(UT-MDACC) Barnhart
2011 3
Smilow Cancer Hospital I
Herbst 1984 6 1990 6
1991 5 Cornell University Medical College
1997 11 2012 12
54
2018 6
2018 6
1989 8 1995 3 1995 3 1999 7
1999 7 1999 12 2000 1 2006 3
2006 3
2022 5
301078. SZ
1989 7 2004 12 2015
11 2017 9
2017 12 2021 7
68
65
2020 6
2020 6
1978 8 1992 7
1992 8 1993 12 1993 12 1995 12
1995 12 1999 12
1999 12 2010 9 2010 9 2017 8
2017 8
1985 7 2001 12 1994
1997 12
66
2021 12
2021 12
1975 12 1978 2 1982 12 2016 11
2000 4 2008 5 2007
5 2011 6 2011 5 2015 7
2016 8 2016 11
2018 1 2018 10
1982 12 1988 12
69
37
2018 6
2018 6
2011 3 2014 3 2016
1 2017 4 股份有限 2017 10
2021 11 2008 6
2011 1
41
2018 6
2018 6
2006 3 2003 6
2006 1 2006 9
32
2021 6
2021 4
2021 4 2021 9
2022 10 2022 12
2022 12
2016 11 2017 5 NBC 2018 4 2018 6
2018 7 2021 3 ABB
2014 2016
70
65
2019 8 1995 10
1998 6 1998 6 1999 7 Osiris
Therapeutics 1999 8 2003 8 2003 8 2005
6 2005 6 2017 4 FDA
2017 4 2018 4 NMPA
2018 5 2019 8 2021 1
688238.
SH 2021 6 1995
44
2020 11 2004 6 2011 5
2011 5 2013 4 2013
4 2020 2 2020 2 2020 11
2021 6
2004
31
2018 1 2017 4 2017 4 2018 1
2014 7 2015 11
2017 11
2019 10
71
20
72
73
14 7 2 5
2022 6 29
2022 12 8
Roy Steven Herbst
59 68
74
3.13
B.2.2
75
76
2022 12 31
A/B
A/B
A/B
A/B
A/B
A/B
2022 6 29 A/B
A/B
A/B
2022 12 8 A/B
A/B
Roy Steven Herbst A/B
A/B
A/B
A/B
A
B
77
3.10(2)
(i)
(ii) (iii)
2022
12
78
2022 12 31
79
49 8 2015 3 27
61 4 2018 6 24
58 6 2016 12 22
46 8 2015 3 27
55 6 2016 12 22
47 6 2016 12 22
2022 6 29 51 1 2022 6 29
49 6 2016 12 22
54 7 2015 5 30
2022 12 8 49 4 2018 6 24
65 4 2018 6 24
Roy Steven Herbst 60 4 2018 6 24
54 4 2018 6 24
65 2 2020 6 19
66 1 2021 12 16
2022 12 31 1,382(46.67%) 1,579(53.32%)
80
1.
2.
a)
b)
c)
d)
e)
f)
g)
h)
81
Roy Steven Herbst
A.2
82
(1)
11/11 – 4/4 2/2 1/1 2/2
11/11 – 4/4 – 1/1 2/2
11/11 – – – – 2/2
11/11 – – – – 2/2
11/11 – – – – 2/2
11/11 – – – – 2/2
2022 6 29 5/5 – – – – –
11/11 – – – – 2/2
11/11 4/4 – – – 2/2
2022 12 8 ) 10/10 – – – – 2/2
11/11 – – – 1/1 2/2
Roy Steven Herbst 11/11 – – – 1/1 2/2
11/11 4/4 4/4 2/2 – 2/2
11/11 4/4 4/4 – 1/1 2/2
11/11 – 4/4 2/2 – 2/2
(1) 2 1 1
83
84
177 178
3,270,00
1,412,000
3,270,000
3,270,000
1,412,000
1,030,000
382,000
4,682,000
85
3.29 15
10%
86
3%
3% 10
2
H
16 17
+852 2810 8185
A
100 6 7 16
200126
+86 021 6175 7377
+86 021
6105 8800
87
F.1.1
(1)
(2)
(3)
10%
50%
88
25%
D.2.6
D.2.7
B.1.4
89
90
2022 1 1 2022 12 31 2022
TopAlliance Biosciences, Inc.
TopAlliance
91
( www.hkex.com.hk) ( www.sse.
com.cn) ( www.junshipharma.com)
92
2012
2018 12 2020 7
(GMP)
GMP
TopAlliance Fc
93
2022 14.53
2022
4 30
PARP III 20
14.53 23.84
SARS-CoV-2 1 VV116/JT001 NMPA
COVID-19
NMPA
6
NMPA
8
94
2022
2022 1 E 2021 10
2022 2 (JS016)
2022 3 2021
2022 4
2022 6 (2021)
(2021)
95
2022 7 2021-2022 SGI
2022 9 E 2022 TOP100
2022 11 2022
2022
2021
2022 12 2022
ESG
96
SARS-COV-2 1
VV116/JT001
SARS-CoV-2 RNA RNA (RdRp) RdRp
SARS-
CoV-2
+
2020 1
RdRp
2021 10
97
2021 11
2021 12
COVID-19
2022 12 29 The New England Journal of Medicine ,
NEJM 176.082 VV116
(PAXLOVID) COVID-19 III
(NCT05341609) NEJM COVID-19
PAXLOVID
98
2023 1 28
NMPA COVID-19
III (NCT05582629)
COVID-19
28 SARS-CoV-2
1,277
11 COVID-19 =0
2 2
COVID-19
99
2023 2
SARS-CoV-2
COVID-19 COVID-19
100
3060
101
17
1.
102
2.
103
3.
1
2
3
6
5 4
8 7
9
10
11
13
12
15
16
17
14
2022
104
1.
2022
2022
105
2.
2022
SOP
3.
(www.hkex.com.hk) (www.sse.com.
cn) (www.junshipharma.com)
106
4.
107
108
(ADCs)
1.
2022
23.84 15.26%
109
2.
2022 50
2022
2022 1
(CSCO)
110
JT001-010
2022 12 29 The New England
Journal of Medicine , NEJM 176.082 VV116
(PAXLOVID)
COVID-19 III (NCT05341609)
NEJM COVID-19
PAXLOVID
JUPITER-06 Cancer Cell
2022 3 JUPITER-06
Cell Press Cancer Cell 31.734
TP +
(ESCC) (PFS)
(OS) PD-L1 (ORR)
(DCR)
111
(AACR 2022)
2022 4 113 (AACR)
(RM NPC)III JUPITER-02
(PFS) (OS)
CT226
PFS 21.4vs.8.2 13.2
48%
(ASCO 2022)
2022 6 (ASCO)
ASCO
PD-1
BTLA ticatolimab(TAB004/JS004) ASCO 40
112
(ASH 2022) BTLA
2022 12 BTLA
tifcemalimab(TAB004/JS004) 2022 64 (ASH 2022)
(#1613) I
tifcemalimab
3.
121 94 27
113
114
1.
2022
4 2022 5
2022 12
2022 GMP
115
GMP
GMP
2022 GMP
17 ICH Q5A
GMP
300
2
MAH MAH
116
2020
(EQS)
EQS 4 GMP QMS(Quality Management System)
TMS(Training Management System). DMS(Documentation
Management System) LIMS(Laboratory Information Management
System)
MAH EOS
2018
GMP
117
2021
118
2021 FDA (RIE)
RIE RIE
2.
2022
100%
119
24
ADR
2022
120
2022
3.
2022
SOP
2022
7
2,681
93%
121
195
2,486
2022
122
123
2022
124
1.
2022
2022
84,685.31 41,711.67 41,807.95
1,160.12 5.57 38,188.98
8,844.82
29,344.16
49%
1%
49%
1%
125
2022 475,333.60
3060
2022
(BMS)
126
2.
EHS EHS
2021
2022
2022
127
2022 4.73 (NOx)4.61
(SOx)0.12
2022
2022 COD PH
2022 159.92
209.80
128
3.
129
130
1.
2022
2022
2022 2,961
53%
131
3%
53% 40%
47%
57%
2022
2022
132
2022
IT
Transformation in Change
2021 76% 2022 100%
2022
2022 9
2021
2022
2022
133
2022
GMP
2022 10
134
2022
6 9
2022
135
2.
2022 1,769.07
1.
2022 8
136
2.
11 17 2022
11
39,000
3.
PD-1
2022 12 Hikma (Hikma Pharmaceuticals PLC)
20
PD-1
137
2022 2
2021 2020 2019
A1.1 1
NOX 4.61 4.06 4.96 3.82
SOX 0.12 0.04 0.004 0.002
4.73 4.10 4.96 3.82
0.003 0.001 0.003 0.005
A1.2
1 3
8,844.82 8,069.64 5,783.59 3,812.70
2 4
29,344.16 27,465.40 23,861.66 13,007.78
38,188.98 35,535.04 29,645.25 16,820.48
1& 2 26.28 8.83 18.59 21.70
A1.3
159.92 140.50 137.27 63.65
0.11 0.03 0.09 0.08
A1.4
5
209.80 274.80 183.00 615.00
0.14 0.07 0.11 0.79
1
(EMFAC-
HK Vehicle Emission Calculation)
2
2022 2021 2022
2021
3
4
5
2022 2021
138
2022 2
2021 2020 2019
A2.1 6
41,711.67 40,820.20 33,918.49 18,490.09
41,807.95 37,289.90 27,660.00 18,227.66
1,160.12 1,744.45
5.57
84,685.31 79,854.55 61,578.49 36,717.75
58.28 19.84 38.61 47.37
A2.2
475,333.60 411,962.40 303,598.00 194,273.00
327.14 102.35 190.36 250.65
A2.5
9.18 9.36 17.04 10.95
17.29 16.81 14.39 9.81
26.47 26.17 31.44 20.76
0.02 0.01 0.02 0.03
6
139
2022 2021 2020 2019
B1.1
2,961 2,805 2,453 1,421
1,382 1,343 1,230 738
1,579 1,462 1,223 683
2961 2,805 2,453 1,357
0 0 0 29
0 0 0 35
≤30 1,175 1,337 1,144 596
31~49 1,706 1,407 1,249 759
≥50 80 61 60 66
2,929 2,777 2,437 1,410
32 28 16 11
B1.2
27.22% 26.85% 24.39% 16.71%
21.99% 20.33% 19.41% 18.14%
≤30 27.91% 19.41% 19.66% 15.80%
31~49 22.14% 27.44% 24.60% 19.61%
≥50 21.57% 16.44% 11.11% 8.20%
24.70% 23.73% 22.04%
3.03% 6.67% 7.41%
B2.1
B2.2
250 136
140
2022 2021 2020 2019
B3.1
100.00% 80.49% 70.57% 73.58%
100.00% 72.09% 70.07% 68.52%
100.00% 53.07% 53.21% 38.00%
100.00% 70.40% 74.51% 50.18%
100.00% 79.83% 70.73% 79.89%
B3.2
104.07 36.82 27.72 72.69
80.46 30.15 26.86 68.75
17.74 14.00 15.28 35.70
25.92 12.31 18.26 49.62
117.82 41.25 30.59 80.21
141
A A1
2.
(a)
(b)
A1.1
A1.2
1 2
A1.3
A1.4
A1.5
2.
A1.6
2.
142
A2
1.
A2.1
A2.2
A2.3
1.
A2.4
1.
A2.5
143
A3
1.
2.
A3.1
1.
2.
A4
3.
A4.1
3.
B B1
1.
(a)
(b)
B1.1
B1.2
144
B2
1.
(a)
(b)
B2.1
B2.2
B2.3
1.
B3
1.
B3.1
B3.2
B4
1.
(a)
(b)
145
B4.1
1.
B4.2
1.
B5
3.
B5.1
3.
B5.2
3.
B5.3
3.
B5.4
3.
146
B6
1.
2.
(a)
(b)
B6.1
2.
B6.2
2.
B6.3
3.
B6.4
1.
2.
B6.5
2.
147
B7
1.
(a)
(b)
B7.1
1.
B7.2
1.
B7.3
1.
B8
2.
B8.1
2.
B8.2
2.
148
50
34
41 56
179 180
149
2023 1 (SARS-CoV-2)1
NMPA COVID-19
2023 1 JS401 3(ANGPTL3) RNA
RNA IND NMPA
2023 1
III Neotorch NCT04158440 IDMC
EFS
2023 2
IV
III TORCHLIGHT NCT04085276
IDMC
2023 2 PCSK9 JS002
III JS002-003 JS002-
006
2023 2
MHRA
2023 3 JS010 CGRP IND NMPA
2023 3 Excellmab
Excellmab 40%
Excellmab Excellmab
452
Excellmab
150
IND
50
151
(i) 9.44% 2021 35.56% 24.89% 2021
46.51%
(ii) 21.66% 2021 62.80%
72.91% 2021 96.19%
5%
152
14
2022 12 31 34
29
2022 12 31 982,871,640 763,575,940 A 219,295,700 H
2022 12 31
2022 12 31 25
153
2018
2018 5 14 2018
2019 6 17 2018 2019
2019 H
2019 5 27 2018
2020 5 11 2019 2020
2020 H 2020 4 20
2018 3 12 268 6,023,000
A 0.79% 0.61%
2018
2018
2018
(a)
2018
2018
12
2018
(b) 2018
2018
154
(c) 2018
2022 12 14 29
(d)
2018
(e) 9.2
2018
(f) 6,023,000
(g) 12
(h) 2018
25%
12 5
35% 5
17 40%
17 29
(i)
155
H 2018
2018
2021 12 16 2018
187 A 9.2 1,845,200
2022 7 7 2018
1,845,200 A 0.19%
187 16,975,840 1,845,200
15,130,640 A
2018
2021 12 16 2022 7 5
2022 2022
(1)
A 1 1 (2)
12 31
2018 2019 3 12 9.2 4,000 – 4,000 – – –
3 12 2022 12 14
186 2018 2019 3 12 9.2 1,841,200 – 1,841,200 – – –
3 12 2022 12 14
1,845,200 – 1,845,200 – – –
156
(1) 25% 12
5 35%
5 17
40% 17
29
(2)
(3) 1,845,200 A A
76.75
(4) 12
31
2018
157
2020 A
2020 9 29 2020 A 2020 A
2020 11 16 2020 2020 A 2020 H
2020 A
2020 A
(a) 2020 A
(b) 2020 11 16 2020 A
1,933 28,519,000
(c) 2020 A 2020 11
16 2020 2020 A 2020 H
12 12
(d) 2020 A 35,648,000 A
A 4.65% 3.62% 2020 A
7,129,000 A 20%
A
158
(e) 1%
(f) 2020 A 2020 11 16
48
(g)
(1) 40% 12
24 (2)
30% 24 36
(3) 30% 36
48
(1) 50% 12
24 (2)
50% 24 36
(h) A 55.50
A A
55.50
(i) 2020 A A 2020 9 29
A 50% A 85.46 (ii) 20 60
120 A 50% 20 A 90.25
159
A 2020 7 15 A 55.50
(i) 2020 A
(j)
2022 12 31 269,740 A 2022 11 1
13,976,580 2022 11 16
2020 A
2022 2022
(1) (2) (3)
1 1 (2)
12 31
2020 11 16 2021 11 16 55.50 820,000 – 100,000 228,000 – 492,000
(4)
2024 11 15
2020 11 16 2021 11 16 55.50 1,560,000 – 20,000 604,000 – 936,000
(4)
2024 11 15
2020 11 16 2021 11 16 55.50 820,000 – 20,000 308,000 – 492,000
(4)
2024 11 15
2020 11 16 2021 11 16 55.50 2,000,000 – – 80,000 – 1,920,000
(4)
2024 11 15
2020 11 16 2021 11 16 55.50 820,000 – 20,000 308,000 – 492,000
(4)
2024 11 15
160
2022 2022
(1) (2) (3)
1 1 (2)
12 31
2020 11 16 2021 11 16 55.50 270,000 – 10,000 98,000 – 162,000
2024 11 15
2020 11 16 2021 11 16 55.50 80,000 – 2,000 30,000 – 48,000
2024 11 15
2020 11 16 2021 11 16 55.50 80,000 – 2,000 30,000 – 48,000
2024 11 15
(5)
2020 11 16 2021 11 16 55.50 30,000 – – 12,000 – 18,000
2024 11 15
2020 11 16 2021 11 16 55.50 17,765,300 – 95,740 9,987,280 – 7,682,280
2024 11 15
24,245,300 269,740 11,685,280 12,290,280
(1) 2020 11 16
(2) (1) 40% 12
24 (2) 30%
24 36 (3)
30% 36 48
(3) A 55.50 A A 71.27
(4) 14A
(5) 14A
(6)
161
2020 A
2022 2022
(1) (2) (3)
1 1 (2)
12 31
2021 11 15 2022 11 15 55.50 7,129,000 – – 2,291,300 – 4,837,700
2024 11 14
(1) 2021 11 15
(2) (1) 50% 12
24 (2) 50%
24 36
(3) A 55.50
(4)
31
2020 A 2020 10 22
2020 11 16 2020 11 17 2021 11 15 2022 11 3 2022 11 16
A 33,219,500 A A
4.76%
2020 A
162
2022 6 29
2022 12 8
Roy Steven Herbst
13.51B(1)
2021 13.51B(1)
163
2022 5 20
2021 10 14
2022 12 8
2022 12 8
164
3.13
3.13
12
2022 12 31
XV XV 7 8
352
165
(1) (1) (1)
share capital(1)
(2)
A 88,346,018 (L) 11.57% 8.99%
H 2,600 (L) 0.00% 0.00%
(2)
A 129,978,568 (L) 17.02% 13.22%
(3)
A 956,000 (L) 0.13% 0.10%
A 3,657,600 (L) 0.48% 0.37%
(4)
A 13,652,000 (L) 1.79% 1.39%
/ (5)
A 9,120,000 (L) 1.19% 0.93%
(6)
A 1,200,000 (L) 0.16% 0.12%
A 7,774,500 (L) 1.02% 0.79%
(7)
A 196,643,786 (L) 25.75% 20.01%
H 2,600 (L) 0.00% 0.00%
1. L S P 2022 12 31
982,871,640 763,575,940 A 219,295,700 H
2. 2022 12 31 88,346,018 A 2,600 H 2020 A
492,000
(i)
2017 12 25 2017 2022 12
31 2017 108,297,768 A
41,060,000 A (ii)
2019 7 26 2019 2022 12 31
2019 21,680,800 A
166
2022 12 31 (i) 20%
4,372,144 A 2017 (ii)
40%
4,600,000 43,584,000 A 2017
86.28% 52,556,144 A
3. 2022 11 3 2020 20,000 A
2022 12 31 2020 A 936,000
4. 2022 12 31 13,652,000 A 2020 A 492,000
5. 2022 12 31 8,608,000 A 2022 11 3
2020 20,000 A 2020 A
492,000
6. 2022 12 31 2020 A 1,200,000
7. 2022 12 31 7,774,500 A 60%
86.28%
2017
2022 12 31
XV
352
167
XV
2022 12 31
XV 2 3
336
(1) (2) (2)
(3) (4)
A 41,060,000 (L) 5.38% 4.18%
A 155,583,786 (L) 20.38% 15.83%
A 43,584,000 (L) 5.71% 4.43%
(4)
A 153,059,786 (L) 20.05% 15.57%
A 4,600,000 (L) 0.60% 0.47%
(4)
A 192,043,786 (L) 25.15% 19.54%
(4)
A 4,372,144 (L) 0.57% 0.44%
A 192,271,642 (L) 25.18% 19.56%
(4)
A 4,288,400 (L) 0.56% 0.44%
A 192,355,386 (L) 25.19% 19.57%
(4)
A 3,789,720 (L) 0.50% 0.39%
A 192,854,066 (L) 25.26% 19.62%
(4)
A 3,719,504 (L) 0.49% 0.38%
A 192,924,282 (L) 25.27% 19.63%
(4)
A 2,884,000 (L) 0.38% 0.29%
A 193,759,786 (L) 25.38% 19.71%
(5)
A 21,680,800 (L) 2.84% 2.21%
88,346,018 (L) 11.57% 8.99%
(6) (8)
A 78,852,000 (L) 10.33% 8.02%
168
(1) (2) (2)
H 30,659,000 (L) 13.98% 3.12%
(8)
(6)
A 76,590,000 (L) 10.03% 7.79%
(6)
A 76,590,000 (L) 10.03% 7.79%
(6)
A 76,590,000 (L) 10.03% 7.79%
(6)
A 78,852,000 (L) 10.33% 8.02%
A 78,852,000 (L) 10.33% 8.02%
(6)(8)
(7)(8)
H 30,659,000 (L) 13.98% 3.12%
Loyal Valley Capital Advantage Fund LP (7)(9)
H 10,106,000 (L) 4.61% 1.03%
Loyal Valley Capital Advantage Fund H 10,106,000 (L) 4.61% 1.03%
GP Limited(7)
Loyal Valley Capital Advantage Fund II LP(7)(9) H 12,127,000 (L) 5.53% 1.23%
Loyal Valley Capital Advantage Fund II H 12,127,000 (L) 5.53% 1.23%
Limited (7)
LVC Renaissance Fund LP(7) H 14,956,000 (L) 6.82% 1.52%
LVC Renaissance Limited (7)
H 14,956,000 (L) 6.82% 1.52%
LVC Holdings Limited (7)
H 22,233,000 (L) 10.14% 2.26%
LVC Management Holdings Limited (7)
H 22,233,000 (L) 10.14% 2.26%
LVC Bytes Limited H 37,189,000 (L) 16.96% 3.78%
LVC Innovate Limited (7)
Jovial Champion Investments Limited(7) H 37,189,000 (L) 16.96% 3.78%
Vistra Trust (Singapore) Pte. Limited (7)
H 37,189,000 (L) 16.96% 3.78%
Highbury Investment Pte Ltd(9) H 7,490,489 (L) 3.42% 0.76%
H 12,127,000 (L) 5.53% 1.23%
169
(1) (2) (2)
GIC (Ventures) Pte. Ltd.(9) H 19,617,489 (L) 8.95% 2.00%
GIC Special Investments Private Limited (9)
H 19,617,489 (L) 8.95% 2.00%
GIC Private Limited (9)
H 18,817,489 (L) 8.58% 1.91%
H 690,000 (L) 0.31% 0.07%
Hillhouse Capital Advisors, Ltd.(10) H 11,400,000 (L) 5.20% 1.16%
H 51,386,400 (L) 23.43% 5.21%
H 10,947,946 (L) 4.99% 1.11%
12,503,584 (S) 5.70% 1.27%
1. L S P
2. 2022 12 31 982,871,640 763,575,940 A 219,295,700 H
3. 2022 12 31 41,060,000 A 2017
2017 155,583,786 A
88,346,018 A 2020 A 492,000
4. 2017 2017
A
5. 2019 2019
6. 2022 12 31 76,590,000 A
2,262,000 A
99.99%
76,590,000 A A
170
7. 2022 12 31 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage Fund
II LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I H
Loyal Valley Capital Advantage Fund II Limited LVC Fund II GP LVC Fund II
H LVC Renaissance Limited LVC Renaissance GP LVC Renaissance Fund
H
LVC Fund I GP LVC Fund II GP LVC Holdings Limited LVC Management Holdings
Limited LVC Holdings Limited LVC Management Holdings Limited LVC Fund I
LVC Fund II H
LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Innovate Limited LVC Bytes Limited
LVC Innovate Limited Jovial Champion Investments Limited
Vistra Trust(Singapore) Pte. Limited LVC Innovate Limited LVC Bytes
Limited Jovial Champion Investments Limited Vistra Trust (Singapore) Pte. Limited LVC Funds
H Vistra Trust (Singapore) Pte. Limited
LVC Renaissance Fund(i) Golden Valley Global Limited 20.13%
99.99%
(ii) Loyal Valley Innovation Capital (HK) Limited
33.28% LVC Funds
37,189,000 H
8. 2022 12 31
76,590,000 A
2,262,000 A
9. 2022 12 31 Highbury Investment Pte Ltd Highbury 12,127,000 H Highbury LVC
Fund II 90.90% LVC Fund II 12,127,000 H Highbury GIC (Ventures) Pte.
Ltd. GIC Ventures GIC Special Investments Private Limited GIC SIPL
GIC Private Limited GIC Private GIC Ventures GIC SIPL GIC Private
Highbury H
10. 2022 12 31 Hillhouse Capital Advisors, Ltd. Gaoling Fund, L.P. YHG Investment, L.P.
Gaoling Fund, L.P. YHG Investment, L.P. 10,715,000 H 685,000 H
2022 7 5
1,845,200 A 2019
5 27 2020 4 20
2021 12 16 2022 7 5
171
2022 11 1 2020 269,740 A
2021 11 15 2022 11 3
2022 12 2 53.95 70,000,000 A
2022 3 7 2022 4 6
2022 6 14 2022 9 16 2022 11 3 2022 12 6
14A
14A
33
12 14A.76 14A.95
14A
12
172
H
20%
20%
H
[2008]897 H 2008 10%
2022 H
173
72 88
89 147
8.08(1)
H
(a) 16%;
(b) H
(c) H
2018 A
(i) 18A.07 H
375 (ii)
15.71%
174
10
2022 12 31
2022 12 31
H
H
2023 3 30
*
175
179 294
2022 12 31
2022 12 31
176
2022 12
31 2,384,373,000
24 2022 12 31
415,751,000
177
178
2023 3 30
179
2022 12 31
12 31
2022 2021
5 1,453,493 4,024,841
(526,282) (1,258,187)
927,211 2,766,654
6 95,890 123,762
7 92,245 74,237
(47) 342
(2,384,373) (2,068,739)
(715,704) (734,563)
(578,269) (647,950)
(1,550) 35
(69,482) (48,498)
(11,753) (36,095)
8 (29,370) (21,833)
9 (2,675,202) (592,648)
10 93,107 (135,533)
(2,582,095) (728,181)
(116,118) 19,454
47,499 (9,852)
(68,619) 9,602
(2,650,714) (718,579)
180
2022 12 31
12 31
2022 2021
(2,386,067) (718,557)
(196,028) (9,624)
(2,582,095) (728,181)
(2,454,686) (708,955)
(196,028) (9,624)
(2,650,714) (718,579)
11
(2.60) (0.80)
(2.60) (0.80)
181
2022 12 31
12 31
2022 2021
14 2,979,327 2,727,809
15 299,129 341,983
16 98,913 40,251
17 109,506 16,056
18 383,133 441,736
28 228,427 88,550
21 362,749 533,914
22 910,197 1,027,108
23 – 1,574
5,371,381 5,218,981
19 599,021 484,601
20 232,725 1,292,933
21 345,137 549,141
23 31,086 459
23 5,996,936 3,504,605
7,204,905 5,831,739
24 1,338,400 1,907,523
25 391,750 10,596
26 440 3,683
27 43,664 34,472
– 60,361
1,774,254 2,016,635
5,430,651 3,815,104
10,802,032 9,034,085
182
2022 12 31
12 31
2022 2021
25 839,582 490,000
26 121,615 118,776
27 46,585 93,127
1,007,782 701,903
9,794,250 8,332,182
29 982,872 910,757
8,518,544 7,050,146
9,501,416 7,960,903
292,834 371,279
9,794,250 8,332,182
179 294 2023 3 30
183
2022 12 31
2021 1 1 872,496 8,574,352 25,565 32,777 – – (9,393) (3,654,534) 5,841,263 (3) 5,841,260
– – – – – – – (718,557) (718,557) (9,624) (728,181)
– – – – – 19,454 – – 19,454 – 19,454
– – – – – – (9,852) – (9,852) – (9,852)
– – – – – 19,454 (9,852) (718,557) (708,955) (9,624) (718,579)
H 29(a) 36,549 2,097,832 – – – – – – 2,134,381 – 2,134,381
H – (30,434) – – – – – – (30,434) – (30,434)
a – – – – 514,094 – – – 514,094 380,906 895,000
31 – – – 2,499 – – – – 2,499 – 2,499
31 – – 192,309 – – – – – 192,309 – 192,309
1,712 30,242 – (16,208) – – – – 15,746 – 15,746
2021 12 31 910,757 10,671,992 217,874 19,068 514,094 19,454 (19,245) (4,373,091) 7,960,903 371,279 8,332,182
– – – – – – – (2,386,067) (2,386,067) (196,028) (2,582,095)
– – – – – (116,118) – – (116,118) – (116,118)
– – – – – – 47,499 – 47,499 – 47,499
– – – – – (116,118) 47,499 (2,386,067) (2,454,686) (196,028) (2,650,714)
184
2022 12 31
A 29(b) 70,000 3,706,500 – – – – – – 3,776,500 – 3,776,500
A – (31,697) – – – – – – (31,697) – (31,697)
a – – – – 258,875 – – – 258,875 121,125 380,000
b – – – – (132,283) – – – (132,283) (53,967) (186,250)
38 – – – – – – – – – 49,000 49,000
31 – – 91,857 – – – – – 91,857 1,425 93,282
1,845 34,199 – (19,068) – – – – 16,976 – 16,976
270 18,499 (3,798) – – – – – 14,971 – 14,971
– 132,205 (132,205) – – – – – – – –
2022 12 31 982,872 14,531,698 173,728 – 640,686 (96,664) 28,254 (6,759,158) 9,501,416 292,834 9,794,250
(a) 2021 12 16
A 12.75 2021 12 31 A
8.95 2022 12 31 A
3.8
(b) 2022 5 17 186,250,000
68.125% 71.85%
185
2022 12 31
12 31
2022 2021
(2,675,202) (592,648)
232,615 215,825
51,117 41,469
9,922 5,265
21,974 13,647
91,911 192,754
(61,018) (30,979)
29,370 21,833
(1,451) (2,830)
9,277 (114,208)
(28,847) –
1,838 34
(16,100) –
(8,109) –
(83,506) 16,198
(7) –
(245) –
47 (342)
1,550 (35)
69,482 48,498
(2,355,382) (185,519)
(136,394) (154,823)
971,476 (629,062)
330,624 (250,010)
(479,565) 734,292
1,047 (19,170)
(1,668,194) (504,292)
(107,131) (137,609)
(1,775,325) (641,901)
186
2022 12 31
12 31
2022 2021
58,299 30,979
(383,101) (772,346)
1 11
(10,851) (14,497)
– (99,385)
(2,826) (19,774)
2,808 3,663
(29,512) (2,033)
459 –
38 2,220 –
(95,000) (15,000)
(1,000) (425,084)
(8,484) (1,169,620)
– 565,284
245 –
3,170 1,176
(4,047) (4,976)
– 40,650
(467,619) (1,880,952)
H – 2,134,381
H (612) (29,677)
A 3,776,500 –
A (28,944) –
840,362 500,000
(113,445) (793,333)
(25,551) (22,472)
(40,815) (33,959)
(186,250) –
386,000 895,000
35,764 15,746
4,643,009 2,665,686
187
2022 12 31
12 31
2022 2021
2,400,065 142,833
3,504,605 3,384,998
92,266 (23,226)
5,996,936 3,504,605
188
2022 12 31
1.
2012 12 27
2015 5 2015 8
833330) 2018 12 24 H
1877) 2020 5 8
2020 7 15 A 688180)
2.
2022 1 1
3
16 2021 6 30
16
37
2018 2020
189
2022 12 31
2.
16
2
2021 1 1
17 1
2020 6 2021 12
17
10
28 2
16 3
1 3
1 3
1 1
2
8 1
12 1
1
2023 1 1
2
3
2024 1 1
190
2022 12 31
2.
12
12 15 24
3
12
2023 1 1
3.
3.1
191
2022 12 31
3.
3.1
2 16
2 36
192
2022 12 31
3.
3.2
193
2022 12 31
3.
3.2
2022 1 1
2018 3
37 21
37 21
194
2022 12 31
3.
3.2
16
(a) 12 (b)
195
2022 12 31
3.
3.2
9
28
36
36
196
2022 12 31
3.
3.2
9
197
2022 12 31
3.
3.2
(a)
198
2022 12 31
3.
3.2
(b)
(c)
199
2022 12 31
3.
3.2
16
200
2022 12 31
3.
3.2
12
201
2022 12 31
3.
3.2
9
202
2022 12 31
3.
3.2
203
2022 12 31
3.
3.2
2022 6 30
16
204
2022 12 31
3.
3.2
205
2022 12 31
3.
3.2
206
2022 12 31
3.
3.2
12
207
2022 12 31
3.
3.2
208
2022 12 31
3.
3.2
209
2022 12 31
3.
3.2
210
2022 12 31
3.
3.2
(a)
(b)
211
2022 12 31
3.
3.2
23
15
212
2022 12 31
3.
3.2
3
213
2022 12 31
3.
3.2
(i)
(ii)
(iii)
214
2022 12 31
3.
3.2
9
9
(i)
215
2022 12 31
3.
3.2
9
(i)
30
(ii)
90
216
2022 12 31
3.
3.2
9
(iii)
(iv)
(v)
217
2022 12 31
3.
3.2
9
(v)
218
2022 12 31
3.
3.2
219
2022 12 31
4.
3
2022 12 31
228,427,000 2021 88,550,000
1,019,982,000 2021 451,455,000
6,057,295,000 2021 3,998,929,000
220
2022 12 31
4.
2022 12 31
697,740,000 2021 568,737,000
36b
5.
2022 2021
752,755 426,636
476,475 3,341,118
6,029 1,066
1,235,259 3,768,820
218,234 256,021
1,453,493 4,024,841
221
2022 12 31
5.
60 2021 60
15
2022 12 31 Coherus
221,508,000 254,967,000
2021 1,111,734,000
2021 12 31 975,150,000 1,254,234,000
45 60 2021
45 60
15
222
2022 12 31
5.
12 31
2022 2021
758,667 427,312
694,826 3,597,529
1,453,493 4,024,841
12 31
2022 2021
4,199,886 4,066,266
32,871 35,483
4,232,757 4,101,749
223
2022 12 31
5.
10%
12 31
2022 2021
Eli Lilly and Company1 254,967 2,366,358
Coherus2 439,742 1,231,171
1
2
6.
12 31
2022 2021
61,018 30,979
a 1,451 2,830
b 32,738 89,061
683 892
95,890 123,762
(a)
(b)
224
2022 12 31
7.
12 31
2022 2021
(9,277) 114,208
38 28,847 –
(1,838) (34)
16,100 –
8,109 –
50,052 (39,937)
245 –
7 –
92,245 74,237
2022 12 31 16,100,000
8.
12 31
2022 2021
22,977 16,053
6,393 5,780
29,370 21,833
225
2022 12 31
9.
12 31
2022 2021
3,270 3,330
242,802 224,834
(10,187) (9,009)
232,615 215,825
54,612 44,964
(3,495) (3,495)
51,117 41,469
9,922 5,265
11,753 25,734
21,974,000
2021 13,647,000
275,191 135,976
352,465 473,595
1,176,624 1,014,026
95,238 120,479
93,282 194,808
(23,538) (12,093)
(76,780) (82,113)
1,264,826 1,235,107
226
2022 12 31
10.
12 31
2022 2021
46,770 197,970
28 (139,877) (62,437)
(93,107) 135,533
25%
2020 11
18 2021 11 30 2021 12 23
2020 2022 2021 2023 2021 2023
15%
15%
2022 12 31
8.84% 2021 8.84%
2022 12 31
46,770,000 2021 197,970,000 2022 12 31 9% 10%
2021 6% 10%)
227
2022 12 31
10.
12 31
2022 2021
(2,675,202) (592,648)
25% 2021 25%) (668,800) (148,162)
388 (9)
17,371 12,124
(2,894) (28,233)
62,945 106,849
(216,036) (176,789)
153,352 41,943
(11,220) (25,658)
523,422 119,262
1,595 36,236
46,770 197,970
(93,107) 135,533
[2022]28 [2018]99 [2021]6 2022 12 31 2021
12 31 175% 200% 2021:175% 200%
228
2022 12 31
11.
(a)
12 31
2022 2021
(2,386,067) (718,557)
12 31
2022 2021
917,465,166 892,659,689
2022 12 31 2022 7 5
1,845,200 2022 11 1 269,740 2022 12 2
A 70,000,000
(b)
2022 12 31 2021 12 31
2022 12 31 2021 12 31
229
2022 12 31
12.
i
2022 12 31
– 7,275 1,881 – 9,156 5,611 14,767
– 4,018 1,081 122 5,221 2,949 8,170
– 4,196 667 133 4,996 2,949 7,945
– 3,658 983 122 4,763 2,949 7,712
– 4,275 734 – 5,009 7,193 12,202
– 4,203 – – 4,203 – 4,203
a – 4,238 – 86 4,324 – 4,324
– 2,296 – – 2,296 – 2,296
– – – – – – –
b – – – – – – –
– – – – – – –
– – – – – – –
– 286 45 79 410 – 410
4,462 – – – 4,462 – 4,462
209 – – – 209 – 209
200 – – – 200 – 200
Roy Steven Herbst 2,001 – – – 2,001 – 2,001
200 – – – 200 – 200
7,072 34,445 5,391 542 47,450 21,651 69,101
230
2022 12 31
12.
i
2021 12 31
– 7,288 18,748 – 26,036 12,333 38,369
– 3,873 1,205 115 5,193 6,483 11,676
– 3,527 645 67 4,239 6,483 10,722
– 3,526 1,096 115 4,737 6,483 11,220
– 3,807 645 – 4,452 15,811 20,263
c – 350 – – 350 – 350
– 2,205 – – 2,205 – 2,205
– – – – – – –
c – – – – – – –
d – – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
e – 130 – 42 172 – 172
f – 118 120 28 266 – 266
f – – – – – – –
f – 508 118 9 635 – 635
5,160 – – – 5,160 – 5,160
g – – – – – – –
200 – – – 200 – 200
Roy Steven Herbst 1,935 – – – 1,935 – 1,935
h 480 – – – 480 – 480
200 – – – 200 – 200
7,975 25,332 22,577 376 56,260 47,593 103,853
231
2022 12 31
12.
(a) 2022 6 2022 4
(b) 2022 12
(c) 2021 11
(d) 2021 6
(e) 2021 6
(f) 2021 6 2021 12 31
(g) 2021 12
(h) 2021 8
(i) 2022 2021 12 31
232
2022 12 31
12.
2021
2021
12 31
2022 2021
8,795 3,354
5,514 2,580
4,568 7,906
18,877 13,840
12 31
2022 2021
9,500,001 10,000,000 1 –
10,000,001 10,500,000 1 –
11,500,001 12,000,000 1 –
13,500,001 14,000,000 – 1
14,000,001 14,500,000 1 1
16,500,001 17,000,000 – 1
17,000,001 17,500,000 1 –
24,000,001 24,500,000 – 1
46,000,001 46,500,000 – 1
13.
2022 2021 12 31
233
2022 12 31
14.
2021 1 1 886,448 914,273 304,757 34,398 26,535 417,348 2,583,759
2,445 1,015 60,286 4,148 30,489 509,505 607,888
13,168 45,135 63,436 – – (121,739) –
(2,986) (10) (950) – – – (3,946)
– – 63 – – – 63
2021 12 31 899,075 960,413 427,592 38,546 57,024 805,114 3,187,764
1,017 1,069 8,954 7,659 7,763 472,913 499,375
38 – – 127 – 786 – 913
141,944 17,435 66,332 – – (225,711) –
(2,047) (194) (5,680) – – (4,131) (12,052)
– – (18) – – – (18)
2022 12 31 1,039,989 978,723 497,307 46,205 65,573 1,048,185 3,675,982
2021 1 1 34,985 102,293 68,651 16,376 13,299 – 235,604
42,494 88,619 71,787 6,001 15,933 – 224,834
(162) (10) (328) – – – (500)
– – 17 – – – 17
2021 12 31 77,317 190,902 140,127 22,377 29,232 – 459,955
44,334 90,800 88,639 5,930 13,099 – 242,802
(424) (92) (5,568) – – – (6,084)
– – (18) – – – (18)
2022 12 31 121,227 281,610 223,180 28,307 42,331 – 696,655
2022 12 31 918,762 697,113 274,127 17,898 23,242 1,048,185 2,979,327
2021 12 31 821,758 769,511 287,465 16,169 27,792 805,114 2,727,809
234
2022 12 31
14.
4.75%
9.50% – 31.67%
19.00% – 31.67%
19.00% – 31.67%
33.33% – 50.00%
2022 12 31 672,430,000 2021 664,538,000
25
228,955,000 2021 93,243,000
15.
2022 12 31
217,182 75,645 6,302 299,129
2021 12 31
224,729 117,254 – 341,983
2022 12 31
7,547 46,095 970 54,612
2021 12 31
5,725 39,239 – 44,964
235
2022 12 31
15.
12 31
2022 2021
4,104 4,233
49 248
51,361 143,605
88,537 200,708
20 50
2021
2022 2021 12 31
2022 12 31 146,166,000 2021 55,611,000
25
2022 12 31 2021
27 36b
236
2022 12 31
16.
2021 1 1 14,394 19,811 98 – 34,303
14,497 – – – 14,497
2021 12 31 28,891 19,811 98 – 48,800
38 – – – 57,733 57,733
10,682 – 766 – 11,448
2022 12 31 39,573 19,811 864 57,733 117,981
2021 1 1 3,277 – 7 – 3,284
5,253 – 12 – 5,265
2021 12 31 8,530 – 19 – 8,549
7,823 – 79 2,617 10,519
2022 12 31 16,353 – 98 2,617 19,068
2022 12 31 23,220 19,811 766 55,116 98,913
2021 12 31 20,361 19,811 79 – 40,251
20% – 50%
10%
5%
2020
19,811,000
237
2022 12 31
17.
12 31
2022 2021
111,000 16,000
(1,494) 56
109,506 16,056
2022 2 28 80,000,000
50%
2022 12 31
15,000,000
2022 2021 2022 2021
12 31 12 31 12 31 12 31
50% 50% 50% 50%
50% 50% 50% 50%
50% 50%
238
2022 12 31
17.
2022
12 31
80,202
(1)
2022
12 31
–
(798)
239
2022 12 31
17.
2022
12 31
80,201
50%
40,101
39,500
79,601
2022 2021
12 31 12 31
(1,151) 35
29,905 16,056
240
2022 12 31
18.
12 31
2022 2021
518,061 495,930
(113,791) (50,857)
(16,100) –
(5,037) (3,337)
383,133 441,736
2022 12 31
12,000,000 2,000,000
1%
20,153,000 38
2022 12 31
32,200,000
2022 12 31
1,000,000
241
2022 12 31
18.
2022 2021 2022 2021
12 31 12 31 12 31 12 31
Anwita Biosciences, Inc 19.53% 19.53% 19.53% 19.53%
Anwita a a a a
50% 50% 50% 50%
50% 50% 50% 50%
50% 50% 50% 50%
(a)
242
2022 12 31
18.
Anwita
12 31
2022 2021
77,295 180,318
68,259 38,410
(20,768) (51,957)
(459) (412)
2022 2021
12 31 12 31
177 40,077
(50,738) (15,189)
243
2022 12 31
18.
Anwita
12 31
2022 2021
Anwita 124,327 166,359
Anwita 19.53% 19.53%
Anwita 24,281 32,490
75,115 75,115
(5,037) (3,337)
Anwita 94,359 104,268
12 31
2022 2021
70,421 153,865
394,681 430,559
(49,040) (64,847)
244
2022 12 31
18.
2022 2021
12 31 12 31
– –
(106,255) (77,188)
(103,515) (80,422)
12 31
2022 2021
416,062 519,577
50% 50%
208,031 259,789
245
2022 12 31
18.
12 31
2022 2021
34,584 39,322
64,416 –
(5,502) (2,009)
2022 2021
12 31 12 31
– –
(11,875) (2,490)
(12,079) (2,687)
246
2022 12 31
18.
12 31
2022 2021
93,498 37,313
50% 50%
46,749 18,657
(16,100) –
30,649 18,657
Anwita
247
2022 12 31
18.
2022 2021
12 31 12 31
(905) (5,322)
50,094 59,022
19.
12 31
2022 2021
338,942 353,059
219,213 102,665
40,866 28,877
599,021 484,601
248
2022 12 31
20.
12 31
2022 2021
232,743 1,285,243
– 7,690
232,743 1,292,933
(18) –
232,725 1,292,933
2021 1 1 663,323,000
12 31
2022 2021
0 – 30 232,364 1,285,217
31 – 90 361 26
180 – 7,690
232,725 1,292,933
2022 12 31 2021 12 31
2021 12 31 7,690,000
36
249
2022 12 31
21.
12 31
2022 2021
17,933 13,780
15,238 16,796
a 239,822 397,383
b 293,562 351,534
c
5,853 4,976
d
– 7,719
11,579 11,579
2,719 –
e
79,424 125,873
42,370 154,005
708,500 1,083,645
(614) (590)
707,886 1,083,055
345,137 549,141
362,749 533,914
707,886 1,083,055
250
2022 12 31
21.
(a)
(b)
(c)
(d) 2021 11 19,298,000
40% 7,719,000 60%
11,579,000
(e) 2022 12 31 79,424,000 2021
125,873,000
42,370,000 2021 154,005,000
2022 12 31
36
251
2022 12 31
22.
12 31
2022 2021
a 156,235 155,218
b 12,182 46,664
c 604,323 551,651
d – 20,000
772,740 773,533
e 137,457 253,575
910,197 1,027,108
(a)
(b)
(c)
92,163,000 2021 78,569,000
(d) 20,000,000 4,687,301
2022 12 31
(e) Coherus
252
2022 12 31
23.
1,574,000
29,512,000 2023 2 2023 6 2021 12 31
459,000 1,574,000 2022 1 2023 9
2022 12 31 0.0001% 4.12% 2021 0.0001% 3.66%)
36
24.
12 31
2022 2021
281,600 196,205
133,382 89,874
a 415,751 227,709
65,783 64,569
75,205 54,149
b 69,097 932,509
c 16,639 15,742
191,903 213,777
35,187 20,579
2,898 757
50,955 91,653
1,338,400 1,907,523
253
2022 12 31
24.
2021 12 31
8,400,000
1,224,000 Anwita
2022 12 31
0 90 2021 15 60
12 31
2022 2021
0 – 30 87,591 143,117
31 – 60 66,244 32,625
61 – 180 72,321 13,473
180 55,444 6,990
281,600 196,205
(a)
(b) 30
(c)
254
2022 12 31
25.
12 31
2022 2021
797,783 500,596
433,549 –
1,231,332 500,596
391,750 10,596
84,836 30,000
397,708 220,000
357,038 240,000
1,231,332 500,596
(391,750) (10,596)
839,582 490,000
2022 2021 12 31
2022 2021
351,362 –
879,970 500,596
1,231,332 500,596
LPR 0.45% 0.85%
2021 0.75%
255
2022 12 31
25.
12 31
2022 2021
1.9% – 2%
3.7% – 3.9% 3.9%
2022 2021
672,430 664,538
146,166 55,611
818,596 720,149
256
2022 12 31
26.
12 31
2022 2021
a 107,875 109,326
b 14,180 13,133
122,055 122,459
440 3,683
121,615 118,776
(a)
(b)
27.
12 31
2022 2021
43,664 34,472
30,712 34,031
15,873 59,096
90,249 127,599
12 (43,664) (34,472)
12 46,585 93,127
4.54% 2021 5.22%)
257
2022 12 31
28.
12 31
2022 2021
228,427 88,550
2021 1 1 6 468 822 24,817 – 26,113
23 2,099 1,388 58,927 – 62,437
2021 12 31 29 2,567 2,210 83,744 – 88,550
5 611 (12) 135,910 3,363 139,877
2022 12 31 34 3,178 2,198 219,654 3,363 228,427
258
2022 12 31
28.
2022 12 31 1,056,038,000 2021 483,490,000
7,172,970,000 2021 4,557,225,000
2022 12 31 36,056,000 2021
32,035,000 1,115,675,000 2021 558,296,000
12 31
2022 2021
698,709 225,816
280,437 205,846
13,804 14,132
6,057,295 3,998,929
27,032 5,661
7,077,277 4,450,384
5,990,659,000 2021 3,921,172,000
66,636,000 2021 77,757,000
259
2022 12 31
29.
1.0
2021 1 1 872,496,000 872,496
H a 36,549,200 36,549
31 1,711,500 1,712
2021 12 31 910,756,700 910,757
A b 70,000,000 70,000
31 1,845,200 1,845
31 269,740 270
2022 12 31 982,871,640 982,872
(a) 2021 6 23 70.18 58.39 36,549,200 H
2,565,023,000 2,134,381,000 36,549,000
2,097,832,000
(b) 2022 12 2 53.95 70,000,000 A
3,776,500,000 70,000,000
3,706,500,000
260
2022 12 31
30.
12 31
2022 2021
754,965 472,493
180,000 192,000
31.
2018 3 12
6,023,000 9.2 2018 5
14
2018 3 12 12 25%
2018 3 12 24 35%
2018 3 12 36 40%
261
2022 12 31
31.
2019 12 31 2020 5
11
9 4
2022 12 31
2022 2022
1 1 12 31
2018 5 14 9.20 2021 12 16 2022 12 15 1,845,200 – (1,845,200) – –
–
9.20 – 9.20 – –
262
2022 12 31
31.
2021 12 31
2021 2021
1 1 12 31
2018 5 14 9.20 2020 12 16 2021 12 15 1,711,500 – (1,711,500) – –
2018 5 14 9.20 2021 12 16 2022 12 15 1,955,200 – – (110,000) 1,845,200
3,666,700 – (1,711,500) (110,000) 1,845,200
1,845,200
9.20 – 9.20 9.20 9.20
A 74.69 2021 83.99
2022 12 31 2021 2,461,000
38,000
263
2022 12 31
31.
A
2020 11 16
A A
A 28,519,000
2020 11 16 12 40%
2020 11 16 24 30%
2020 11 16 36 30%
A
2022 12 31
2022 2022
1 1 12 31
2020 11 16 55.50 2021 11 16 2022 11 15 9,698,120 – (269,740) (9,428,380) –
2020 11 16 55.50 2022 11 16 2023 11 15 7,273,590 – – (1,142,850) 6,130,740
2020 11 16 55.50 2023 11 16 2024 11 15 7,273,590 – – (1,114,050) 6,159,540
24,245,300 – (269,740) (11,685,280) 12,290,280
12,290,280
55.50 – 55.50 55.50 55.50
264
2022 12 31
31.
A
2021 12 31
2021 2021
1 1 12 31
2020 11 16 55.50 2021 11 16 2022 11 16 11,407,600 – (1,709,480) 9,698,120
2020 11 16 55.50 2022 11 16 2023 11 16 8,555,700 – (1,282,110) 7,273,590
2020 11 16 55.50 2023 11 16 2024 11 16 8,555,700 – (1,282,110) 7,273,590
28,519,000 – (4,273,700) 24,245,300
24,245,300
55.50 – 55.50 55.50
2022 12 31 61,280,000 2021
184,785,000 677,000 2021 2,016,000
A
2021 11 15
A A
A 7,129,000
2021 11 15 12 50%
2021 11 15 24 50%
265
2022 12 31
31.
A
A
2022 12 31
2022 2022
1 1 12 31
2021 11 15 55.50 2022 11 15 2023 11 15 3,564,500 – (1,145,650) 2,418,850
2021 11 15 55.50 2023 11 15 2024 11 15 3,564,500 – (1,145,650) 2,418,850
7,129,000 – (2,291,300) 4,837,700
4,837,700
55.50 – 55.50 55.50
266
2022 12 31
31.
A
2021 12 31
2021 2021
1 1 12 31
2021 11 15 55.50 2022 11 15 2023 11 15 – 3,564,500 – 3,564,500
2021 11 15 55.50 2023 11 15 2024 11 15 – 3,564,500 – 3,564,500
– 7,129,000 – 7,129,000
7,129,000
– 55.50 – 55.50
2022 12 31 30,631,000 2021
5,508,000 694,000 2021
32.
50
4% 2%
2022 12 31
91,168,000 2021 118,839,000
4,070,000 2021 1,640,000
267
2022 12 31
33.
(a)
12 31
2022 2021
7,554 23,026
Anwita – 24,627
7,554 47,653
(b)
12 31
2022 2021
– 3,743
(c)
12 31
2022 2021
624 –
268
2022 12 31
33.
(d)
12 31
2022 2021
57,849 82,123
23,201 63,363
753 807
81,803 146,293
269
2022 12 31
34.
2022 2021 12 31
2022 2021
12 31 12 31
Shanghai Junshi Biotechnology Co., Ltd.* 1,000,000,000 100% 100%
2016 6 29 1,000,000,000
Jiangsu Union Biopharm 60,000,000 100% 100%
Pharmaceutical Technology Co., Ltd.* 2013 4 1 13,300,000
Suzhou Junmeng Biopharm Co., Ltd.* 600,000,000 100% 100%
2013 10 12 600,000,000
Suzhou Union Biopharm Co., Ltd.* 750,000,000 100% 100%
2013 10 12 725,600,000
Suzhou TopAlliance Biosciences Co., Ltd.* 500,000,000 100% 100%
2017 7 26 177,748,960
TopAlliance Biosciences Inc. 95,000,000 100% 100%
2013 3 6 616,357,000
95,000,000
616,357,000
Junshi Biomedical Technology (Hainan) 50,000,000 100% 100%
Investment Management Co., Ltd.* 2021 2 9 50,000,000
270
2022 12 31
34.
2022 2021
12 31 12 31
Shanghai JunTop Biosciences Co., Ltd.* 440,366,972 71.85% 68.125%
2021 8 6 440,366,972
Suzhou Junjing Biomedical 51,020,408 51%
Technology Co., Ltd.* 2020 9 23 51,020,408
Beijing Union Biopharm 25,000,000 100% 100%
Junshi Biosciences Co., Ltd.* 2016 6 12 11,200,000
Suzhou Junao Medicine Co., Ltd.* 420,000,000 100% 100%
2018 1 10 52,090,000
Suzhou Junshi Biotechnology Co., Ltd.* 200,000,000 100% 100%
2018 6 19 79,330,000
Shanghai Wangshi Biomedical 10,000,000 35.925% 34.063%
Technology Co., Ltd * 2021 12 31 5,000,000
*
271
2022 12 31
34.
2022 2021 12 31
2022 2021 2022 2021 2022 2021
28.15% 31.875% (192,953) (9,624) 246,912 371,282
(3,075) – 45,922 (3)
(196,028) (9,624) 292,834 371,279
2022 2021 12 31
12 31
2022 2021
1,117,457 1,167,538
276,079 1,870
(147,888) (1,650)
272
2022 12 31
34.
12 31
2022 2021
(17,980) (2,950)
980,756 793,526
384,248 371,282
(137,336) –
2022 2021
1 1 8 6
2022 2021
12 31 12 31
(129,195) (20,568)
(55,617) (9,624)
(137,336) –
(322,148) (30,192)
– –
(414,473) (34,024)
(76,159) (24)
372,324 1,194,848
(118,308) 1,160,800
273
2022 12 31
35.
36.
36a.
12 31
2022 2021
6,313,455 4,853,831
772,740 773,533
137,457 253,575
1,626,232 1,710,079
36b.
274
2022 12 31
36.
36b.
(i)
12 31
2022 2021
859,497 1,734,299
4,908 534,495
(20,441) (22,449)
(8,201) (1,291)
5% 2021 5%)
5%
5%
5% 5%
5%
275
2022 12 31
36.
36b.
(i)
12 31
2022 2021
(41,953) (64,194)
(245) (20,044)
410 48
(ii)
25 21 27
23 25
12 31
2022 2021
61,018 30,979
276
2022 12 31
36.
36b.
(ii)
12 31
2022 2021
22,977 16,053
50 2021 50
50 2021 50
2022 12 31 4,400,000 2021
2,503,000
277
2022 12 31
36.
36b.
(iii)
22
2022 12 31
5% 6,873,000 2021
12,679,000
5%
2021 5%) 2022 12 31 30,825,000
2021 30,916,000
12
12
278
2022 12 31
36.
36b.
2022 12 31
25% 2021 97%) 75% 2021 3%)
36.8% 2021 97%) 2021
18,000 2021
12
2022 2021 12 31
29,000 2021 342,000
279
2022 12 31
36.
36b.
- 12
- 12
- -
- -
280
2022 12 31
36.
36b.
12 2022 2021
23 AA 12 31,086 2,033
23 AA 12 5,996,936 3,504,605
21 12 53,322 54,850
20
147,181 11,971
85,562 1,273,272
– 7,690
6,314,087 4,854,421
9
281
2022 12 31
36.
36b.
2022 2021
0.01%-0.1% 147,181 0.01%-0.1% 11,971
147,181 11,971
2022 2021 12 31
282
2022 12 31
36.
36b.
12
2021 1 1 – 932 932
2021 1 1
– (342) (342)
2021 12 31 – 590 590
2022 1 1
18 278 296
– (249) (249)
– (5) (5)
2022 12 31 18 614 632
25 29
283
2022 12 31
36.
36b.
3
3 1 1-2 2-5 5
%
2022 12 31
– 394,900 – – – – 394,900 394,900
3.74 23,213 399,969 114,957 462,610 380,299 1,381,048 1,231,332
4.54 13,280 37,045 33,550 43,495 – 127,370 90,249
431,393 437,014 148,507 506,105 380,299 1,903,318 1,716,481
2021 12 31
– 1,209,483 – – – – 1,209,483 1,209,483
3.98 9,843 19,398 48,330 261,068 248,628 587,267 500,596
5.22 8,054 26,598 36,791 93,360 – 164,803 127,599
1,227,380 45,996 85,121 354,428 248,628 1,961,553 1,837,678
284
2022 12 31
36.
36b.
(i)
2022 2021
12 31 12 31
2022 20,000 20,000
2021
5,380 1,952 2022 2022
2021 2021
27% EV/
EV/S S 8.69
6,802 6,802
28% 2021
P/R&D 27%) P/R&D 3.28 2021
2.80)
285
2022 12 31
36.
36b.
(i)
2022 2021
12 31 12 31
a 151,167 181,888 2022 2022
P/R&D 21% P/
R&D 13.45
2021 2021
2022 58,964 37,910 2022 2022 2022
2021 2021 P/R&D 28% P/
a R&D 8.28
2021 2021
22,492 28,611 2022 2022 2022
2021
2021 2021
40,556 47,789 2022 2022 2022
2021 P/R&D 24% P/
R&D 9.93
2021 2021
286
2022 12 31
36.
36b.
(i)
2022 2021
12 31 12 31
26,028 23,970 2022 2022 2022
2021 P/R&D 23% P/
R&D 5.28
2021 2021
55,000 46,516
74,430 62,855
92,163 78,569 2022 2022
P/R&D 18% P/
R&D 2.22
2021 2021
63,522 81,453
P/R&D 27% 2021
25%) P/R&D 3.06 2021
5.39)
287
2022 12 31
36.
36b.
(i)
2022 2021
12 31 12 31
156,236 155,218
772,740 773,533
137,457 253,575
910,197 1,027,108
a. 2022 12 31
288
2022 12 31
36.
36b.
(ii)
2021 1 1 95,097 77,030 – 172,127
– – 146,688 146,688
(89,373) – 89,373 –
3,030 62,010 – 65,040
– 16,178 168,704 184,882
2021 12 31 2022 1 1 8,754 155,218 404,765 568,737
– – 148,040 148,040
3,428 1,018 (23,483) (19,037)
2022 12 31 12,182 156,236 529,322 697,740
(iii)
289
2022 12 31
37.
27 25 24
2021 1 1 56,211 794,568 – 850,779
(39,739) (310,025) (29,677) (379,441)
5,780 16,053 – 21,833
– – 30,434 30,434
105,347 – – 105,347
2021 12 31 127,599 500,596 757 628,952
(47,208) 707,759 (29,556) 630,995
6,393 22,977 – 29,370
– – 31,697 31,697
86,754 – – 86,754
38 1,599 – – 1,599
(84,888) – – (84,888)
2022 12 31 90,249 1,231,332 2,898 1,324,479
290
2022 12 31
38.
2022 3 8 2,000,000 50%
51%
913
1,784
57,733
37,107
4,220
(158)
(1,599)
100,000
35,246,000
35,246,000
(49%)
49,000,000
2,000
49,000
49,000
(100,000)
-
291
2022 12 31
38.
50% 49,000
18 (20,153)
28,847
4,220
(2,000)
2,220
2022 1 1 2022 3 8 870,000
6,241,000 2022 12 31
2022 1 1 1,453,493,000
2,581,508,000 2022 1 1
292
2022 12 31
39.
2 5
86,754,000 86,754,000 2021 105,347,000
105,347,000
76,779,000 84,888,000 2021
8,109,000 2021
40.
12 31
2022 2021
296,922 243,624
126,906 149,982
3,818,553 2,927,129
35,640 36,475
29,904 16,056
398,235 441,736
192,900 213,242
1,455,789 719,951
835,768 964,254
7,190,617 5,712,449
57,653 27,249
232,233 1,292,086
271,711 423,716
522,196 672,660
29,515 –
4,715,959 2,004,602
5,829,267 4,420,313
293
2022 12 31
40.
12 31
2022 2021
1,093,786 1,557,717
1,562,153 519,239
23,408 23,692
– 60,361
2,679,347 2,161,009
3,149,920 2,259,304
10,340,537 7,971,753
69,722 –
8,620 8,022
11,929 34,922
90,271 42,944
10,250,266 7,928,809
982,872 910,757
9,267,394 7,018,052
10,250,266 7,928,809
294
2022 12 31
40.
2021 1 1 8,561,533 25,565 32,777 – (3,766,385) 4,853,490
– – – – (131,132) (131,132)
– – – 19,454 – 19,454
– – – 19,454 (131,132) (111,678)
H 2,097,832 – – – – 2,097,832
H (30,434) – – – – (30,434)
– – 2,499 – – 2,499
– 192,309 – – – 192,309
30,242 – (16,208) – – 14,034
2021 12 31 10,659,173 217,874 19,068 19,454 (3,897,517) 7,018,052
– – – – (1,432,457) (1,432,457)
– – – (116,118) – (116,118)
– – – (116,118) (1,432,457) (1,548,575)
A 3,706,500 – – – – 3,706,500
A (31,697) – – – – (31,697)
– 93,282 – – – 93,282
34,199 – (19,068) – – 15,131
18,499 (3,798) – – – 14,701
132,205 (132,205) – – – –
2022 12 31 14,518,879 175,153 – (96,664) (5,329,974) 9,267,394
H
295
2018
2018 2019 7
2018 2018 5 14
2020 7 15
2020 A 2020 11 16 2020 2020
A 2020 H
2020 A
A 1.00
A A
ALK
ANGPTL3 3
ASCO
50%
BLA
BTD
CGMP
Coherus Coherus BioSciences, Inc.
Coherus
296
622
COVID-19
DCR
EFS
EGFR
EMA
ESG
EUA
EFS
Excellmab Excellmab Pte. Ltd.
Coherus 2021 2 1
FDA
GMP
2018
Hikma Hikma MENA FZE
297
H H 2018 12 24
H 1.00
H H
IDMC
IND
Eli Lilly and Company
298
MHRA
mRNA RNA
NDA
NMPA
(2022)
ORR
OS
PDUFA
PFS
2018
2018 12 11
299
RdRp RNA RNA
2022 12 31
2020 A
A 2020 A
Rxilient Biotech Pte. Ltd.
SCLC
571
2016
6
1.00 H A
2018 3
siRNA RNA
sNDA
300
TopAlliance TopAlliance Biosciences Inc.
%
*